World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
79
Citations
21080
World Ranking
1699
National Ranking
838

Guido Ferrari publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Guido Ferrari sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 324 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Guido Ferrari D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Guido Ferrari sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 79 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Guido Ferrari is a researcher affiliated with Duke University in the United States, with a significant focus on immunology, microbiology, and medicine. Their work encompasses multiple specialized subfields, including immunology, virology, infectious diseases, molecular biology, and radiology, nuclear medicine, and imaging.

Their research contributions prominently address key areas such as HIV research and treatment, immune cell function and interaction, monoclonal and polyclonal antibodies research, T-cell and B-cell immunology, HIV/AIDS drug development and treatment, SARS-CoV-2 and COVID-19 research, and vaccines and immunoinformatics approaches.

Guido Ferrari has published extensively, with a notable presence in various academic journals and venues. Frequent publication platforms include UNC Libraries, bioRxiv (Cold Spring Harbor Laboratory), Frontiers in Immunology, Journal of Virology, and Annals of the Rheumatic Diseases.

Their recent papers include the following:

  • Curing HIV: Seeking to Target and Clear Persistent Infection (2020, Cell)
  • Defining the risk of SARS-CoV-2 variants on immune protection (2022, Nature)
  • 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates (2020, Science Immunology)
  • Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (2020, The Lancet HIV)
  • Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates (2021, npj Vaccines)

Throughout their career, Ferrari has collaborated frequently with several researchers, including:

  • David C. Montefiori
  • Georgia D. Tomaras
  • Barton F. Haynes
  • Xiaoying Shen
  • Justin Pollara

In addition to journal articles, Guido Ferrari has participated in book publications, such as the volume titled Fc-Mediated Antibody Functions and Fc-Receptor Polymorphism Volume II, published by Frontiers Media in 2023.

Best Publications

  • Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

    Barton F. Haynes;Peter B. Gilbert;M. Juliana McElrath;Susan Zolla-Pazner

  • The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

    Nilu Goonetilleke;Michael K.P. Liu;Jesus F. Salazar-Gonzalez;Guido Ferrari

  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

    Dan H. Barouch;Dan H. Barouch;Jinyan Liu;Hualin Li;Lori F. Maxfield

  • Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

    Nicole L. Yates;Nicole L. Yates;Hua Xin Liao;Hua Xin Liao;Youyi Fong;Allan DeCamp

  • A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

    Jeffrey R Currier;Ellen G Kuta;Ellen Turk;Lyndsay B Earhart

  • Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

    Mattia Bonsignori;Justin Pollara;M. Anthony Moody;Michael D. Alpert

  • Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

    Georgia D. Tomaras;Guido Ferrari;Xiaoying Shen;S. Munir Alam

  • Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

    Hua Xin Liao;Mattia Bonsignori;S. Munir Alam;Jason S. McLellan

  • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.

    Olivier Lambotte;Guido Ferrari;Christiane Moog;Nicole L Yates

  • An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum

    Guido Ferrari;Justin Pollara;Daniel Kozink;Tiara Harms

  • Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies

    Feng Gao;Mattia Bonsignori;Hua Xin Liao;Amit Kumar

  • Clade B-Based HIV-1 Vaccines Elicit Cross-Clade Cytotoxic T Lymphocyte Reactivities in Uninfected Volunteers

    Guido Ferrari;Will Humphrey;M. Juliana McElrath;Jean–Louis Excler

  • Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity

    Maxime Veillette;Anik Désormeaux;Halima Medjahed;Nour-Elhouda Gharsallah

  • Defining the risk of SARS-CoV-2 variants on immune protection

    Unknown

  • High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.

    Justin Pollara;Lydia Hart;Faraha Brewer;Joy Pickeral

  • Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection

    Takuya Yamamoto;David A. Price;David A. Price;Joseph P. Casazza;Guido Ferrari

  • Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

    Wilton B. Williams;Hua Xin Liao;M. Anthony Moody;Thomas B. Kepler

  • Vertical T cell immunodominance and epitope entropy determine HIV-1 escape

    Michael K.P. Liu;Natalie Hawkins;Adam J. Ritchie;Vitaly V. Ganusov

  • HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC.

    Natasha Wood;Tanmoy Bhattacharya;Tanmoy Bhattacharya;Brandon F. Keele;Elena Giorgi;Elena Giorgi

  • Adjuvant-dependent Innate and Adaptive Immune Signatures of Risk of SIVmac251 Acquisition

    Monica Vaccari;Shari N Gordon;Slim Fourati;Luca Schifanella;Luca Schifanella

  • Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response

    Sharon A. Stranford;Joan Skurnick;Donald Louria;Dennis Osmond

Frequent Co-Authors

Georgia D. Tomaras
Georgia D. Tomaras Duke University
David C. Montefiori
David C. Montefiori Duke University
Barton F. Haynes
Barton F. Haynes Duke University
Hua-Xin Liao
Hua-Xin Liao Duke University
M. Anthony Moody
M. Anthony Moody Duke University
Kent J. Weinhold
Kent J. Weinhold Duke University
M. Juliana McElrath
M. Juliana McElrath University of Washington
Nelson L. Michael
Nelson L. Michael Walter Reed Army Institute of Research
Celia C. LaBranche
Celia C. LaBranche Duke University
S. Munir Alam
S. Munir Alam Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in immunology who also want to explore healthcare roles, pursuing advanced nursing degrees can offer rewarding career routes. Many professionals seek affordable options for further education, making programs like the cheapest psych np programs an attractive choice to gain specialized skills without excessive debt.

Understanding potential earnings is just as important as education. Nurses with a Doctor of Nursing Practice (DNP) credential often experience significant salary growth. The how much do dnp nurses make resource offers state-specific insights into income expectations, helping students plan their careers strategically.

For family nurse practitioners aiming to pivot their focus towards more critical care settings, obtaining additional credentials is essential. Guidance on acute care certification for fnp provides a clear pathway to expanding clinical expertise and job opportunities in acute care environments.

Lastly, accelerated programs enable faster transitions into nurse practitioner roles, suiting those eager to advance quickly. Exploring the nurse practitioner accelerated program options can help prospective students find the format that best fits their needs and lifestyle.

Best Scientists Citing Guido Ferrari

Trending Scientists

Recently Published Articles